---
title: Reduce neuroinflammation and slow progression
nct_id: NCT07157735
phase: PHASE2
status: RECRUITING
sponsor: Cambridge University Hospitals NHS Foundation Trust
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07157735"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07157735"
last_fetched: "2026-05-10T14:02:35.416Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce neuroinflammation and slow progression

**Goal (in five words):** Reduce neuroinflammation and slow progression

**Official Title:** Anti-inflammatory Intervention With Dapansutrile (OLT1177®) for Parkinson's Disease Modification (DAPA-PD): A Randomised Double-Blind, Placebo-Controlled Phase II Trial

**Trial ID:** [NCT07157735](https://clinicaltrials.gov/study/NCT07157735)

## Key Facts

- **Phase:** PHASE2
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Target Enrollment:** 36 participants
- **Start Date:** 2026-02-02
- **Completion Date:** 2027-08
- **Conditions:** Parkinson Disease
- **Interventions:** dapansutrile, placebo
- **Intervention Types:** DRUG

## Summary For Families

The goal is to slow or modify early Parkinson's by reducing harmful brain inflammation that may drive nerve cell damage and symptom progression. The approach gives oral dapansutrile (OLT1177) versus placebo; dapansutrile blocks the NLRP3 inflammasome to lower inflammatory cytokines like IL-1β and IL-18, aiming to dampen microglial-driven inflammation, and it is tested alongside usual care so people can be drug-naive or remain on a stable dopaminergic regimen. They are looking for people aged 50 to 80 with clinically established early PD under 5 years and Hoehn and Yahr stage ≤2, who have hsCRP >1 mg/L, and who meet safety requirements such as no recent immunosuppressive therapy, no active infections or autoimmune disease, and PET-MRI compatibility.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

To be included in the trial, the potential participant must:

* Have given written informed consent to participate.
* Be aged between 50 and 80 years (inclusive) at the time of the screening visit.
* Be a fluent English speaker.
* Have a diagnosis of clinically established early PD according to the Movement Disorder Society Criteria for Clinically Established Early Parkinson's Disease.
* Have a disease duration of less than 5 years at the time of screening visit.
* Have early-stage PD, defined as Hoehn and Yahr stage ≤2.
* Be PD drug naïve or be receiving a stable dose of dopaminergic therapy for at least 3 months prior to screening visit, or between screening and baseline.
* Have hsCRP \> 1 mg/L at screening visit.
* Have adequate organ function, as defined below (to be rechecked prior to baseline/investigational medicinal product \[IMP\] initiation if \>42 days from screening visit): Haemoglobin ≥ 110 g/L; Platelet count ≥ 130 × 109/L; Neutrophil count ≥ 1.5 × 109/L; Renal function: estimated glomerular filtration rate (eGFR) \>45 mL/min/1.73m2; Hepatic function: alanine aminotransferase (ALT) and bilirubin \< 1.5 times the institutional upper limit of normal; Thyroid stimulating hormone (TSH) within normal range; Corrected calcium ≤ institutional upper limit of normal; Alkaline phosphatase (ALP) \< 1.5 times the institutional upper limit of normal

Exclusion Criteria:

The presence of any of the following will preclude inclusion:

* Low affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971.
* Any use of immunomodulatory drugs or biologic agents (such as azathioprine, mycophenolate, methotrexate, ciclosporin, cyclophosphamide etc.) within 12 months prior to screening visit, or between screening and baseline.
* Any previous use of rituximab or alemtuzumab at any time.
* Treatment with oral corticosteroids for greater than 2 weeks within 12 months prior to screening visit, or any oral or injected steroid use within 3 months prior to screening visit, or between screening and baseline.
* Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) - including aspirin \> 75 mg, naproxen, ibuprofen and meloxicam - on more than 2 days per week.
* Known inflammatory or autoimmune disease.
* Chronic or latent infection.
* Severe infection requiring the use of parenteral antimicrobial agents within 2 months prior to screening visit, or between screening and baseline.
* Skin, solid organ or haematological malignancy within the 5 years prior to screening visit, or between screening and baseline.
* The inability to take or swallow oral medication.
* Parkinson's Disease Dementia according to Movement Disorder Society (MDS) PD Dementia criteria.
* A known genetic mutation associated with PD.
* A positive test for human immunodeficiency virus (HIV), hepatitis B (HBV)/C (HCV) or syphilis.
* Chronic liver disease.
* Any concurrent medical or psychiatric condition or disease that is likely to interfere with the trial procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this trial.
* Women of childbearing potential - female participants must be surgically sterile or be post-menopausal. (A post-menopausal state is defined as no menses for 12 months without an alternative medical cause).
* Male participants must be surgically sterile or must agree to use effective contraception during the period of therapy and for 6 months after the last dose of the trial treatment.
* Known hypersensitivity to dapansutrile or its excipients.
* Received an investigational drug or used an invasive investigational medical device within 12 weeks before the screening assessment, or is currently enrolled in another interventional investigational trial. Participants currently enrolled in other observational studies may be recruited.
* Contraindications to PET-magnetic resonance imaging (MRI) scanning including metal implants, claustrophobia or inability to lie flat for 90 minutes.
* Concomitant treatment with any medications that could interfere with \[18F\] DPA-714 binding (e.g., benzodiazepines).
* Current use of any drugs of abuse or average alcohol intake of \>21units per week over the last 3 months.
* Any other significant disease, disability or investigation result which, in the opinion of the Chief Investigator (CI), may either put the participant at risk, or may influence the result of the trial, or the participant's ability to participate in the trial.
```

## Locations (1)

- John Van Geest Centre for Brain Repair, Cambridge, United Kingdom _(52.2000, 0.1167)_

## Central Contacts

- Trial Coordinator — (CONTACT) — 44 1223 331160 — mcd68@cam.ac.uk

---

*Canonical: https://parkinsonspathways.com/trial/NCT07157735*  
*HTML version: https://parkinsonspathways.com/trial/NCT07157735*  
*Source data: https://clinicaltrials.gov/study/NCT07157735*